Shares of Avadel Pharmaceuticals PLC (AVDL) tumbled 21.6% in premarket trading on Thursday after the company said in a securities filing that the Food and Drug Administration requested additional information for its experimental narcolepsy drug. Avadel said it now expects to get a FDA decision on the drug, FT218, by June of next year. The company's stock is down 58.1% this year, while the S&P 500 has declined 16.5%.
Any recommendation, opinion or advice regarding securities or markets contained in such material does not reflect the views of TD Ameritrade, and TD Ameritrade does not verify any information included in such material.
, 
, 
Copyright ©2022. All rights reserved.